GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » General Biologicals Corp (ROCO:4117) » Definitions » Debt-to-Revenue

General Biologicals (ROCO:4117) Debt-to-Revenue : 8.21 (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is General Biologicals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

General Biologicals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$208.7 Mil. General Biologicals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$2,100.9 Mil. General Biologicals's annualized Revenue for the quarter that ended in Dec. 2024 was NT$281.3 Mil. General Biologicals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 8.21.


General Biologicals Debt-to-Revenue Historical Data

The historical data trend for General Biologicals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

General Biologicals Debt-to-Revenue Chart

General Biologicals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.82 1.27 2.08 9.17

General Biologicals Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 1.77 2.10 8.63 8.21

Competitive Comparison of General Biologicals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


General Biologicals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, General Biologicals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where General Biologicals's Debt-to-Revenue falls into.


;
;

General Biologicals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

General Biologicals's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(208.713 + 2100.929) / 251.926
=9.17

General Biologicals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(208.713 + 2100.929) / 281.302
=8.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


General Biologicals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of General Biologicals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


General Biologicals Business Description

Traded in Other Exchanges
N/A
Address
No-6, Innovation First Road, Hsinchu Science Park, Hsinchu, TWN, 300092
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.

General Biologicals Headlines

No Headlines